NCT03101488View on ClinicalTrials.gov

Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

287

Participants

Timeline

Start Date

March 21, 2017

Primary Completion Date

September 2, 2019

Study Completion Date

August 25, 2020

Conditions

Solid Tumors

Interventions

DRUG

KN035

KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.

Trial Locations (4)

100071

Affiliated Hospital of Military academy of medical sciences, Beijing

Unknown

Hunan Cancer Hospital, Changsha

First Affiliated Hospital of Soochow University, Suzhou

Zhongshan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors

lead

3D Medicines (Sichuan) Co., Ltd.

INDUSTRY

NCT03101488 - Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter